| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0039-6257(98)00023-X |
| P698 | PubMed publication ID | 9716190 |
| P2093 | author name string | J C Pastor | |
| P2860 | cites work | The pathophysiology of proliferative vitreoretinopathy in its management | Q93588666 |
| Clinical risk factors for proliferative vitreoretinopathy | Q30460309 | ||
| Results of pneumatic retinopexy with air | Q31035096 | ||
| Fluorosilicone oil in the treatment of retinal detachment | Q33648383 | ||
| Potential antiinflammatory effects of interleukin 4: suppression of human monocyte tumor necrosis factor alpha, interleukin 1, and prostaglandin E2 | Q33858688 | ||
| Growth factors in retinal diseases: proliferative vitreoretinopathy, proliferative diabetic retinopathy, and retinal degeneration | Q36015882 | ||
| Intravitreal chemotactic and mitogenic activity. Implication of blood-retinal barrier breakdown | Q36480503 | ||
| Clinical factors predisposing to massive proliferative vitreoretinopathy in rhegmatogenous retinal detachment | Q36612200 | ||
| Neovascular growth factors | Q36664516 | ||
| Laser endoscope in the management of proliferative vitreoretinopathy | Q36736971 | ||
| Vascular consequences of retinectomy | Q36792222 | ||
| Surgical risk factors for severe postoperative proliferative vitreoretinopathy (PVR) in retinal detachment with grade B PVR. | Q36798472 | ||
| Onset and recurrence of proliferative vitreoretinopathy in various vitreoretinal disease | Q37315556 | ||
| Use of perfluorocarbon liquids in proliferative vitreoretinopathy: results and complications | Q37316989 | ||
| Adhesives in retinal detachment surgery | Q37723865 | ||
| Proliferative vitreoretinopathy--is it anything more than wound healing at the wrong place? | Q37922620 | ||
| Current concepts: immunology. Monocytes and macrophages | Q39631972 | ||
| Pathogenesis and classification of massive periretinal proliferation | Q39632745 | ||
| Origin of fibronectin in epiretinal membranes of proliferative vitreoretinopathy and proliferative diabetic retinopathy | Q39693709 | ||
| Proliferative vitreoretinopathy: pathobiology, surgical management, and adjunctive treatment | Q39713018 | ||
| Traction retinal detachment. XLIX Edward Jackson Memorial Lecture | Q40869093 | ||
| Antiproliferative effect of trapidil, a platelet-derived growth factor antagonist, on a glioma cell line in vitro | Q41722439 | ||
| Management of anterior vitreous traction in proliferative vitreoretinopathy | Q41953224 | ||
| Immunohistochemical demonstration of cellular fibronectin and tenascin in human epiretinal membranes | Q41968954 | ||
| Intravitreal and subretinal proliferation induced by platelet-rich plasma injection in rabbits. | Q42004413 | ||
| Smooth muscle cell migration induced by inflammatory cell products and its inhibition by a potent calcium antagonist, nilvadipine | Q42143893 | ||
| Retinal pigment epithelial cells in epiretinal membranes: an immunohistochemical study | Q42612182 | ||
| Inhibition of mitogenic activity of PDGF, EGF, and FGF by interferon-gamma | Q42801390 | ||
| Suppression of human retinal pigment epithelial cell proliferation by hyperthermia | Q43432373 | ||
| Inhibition of intraocular fibrin formation following infusion of low-molecular-weight heparin during vitrectomy | Q43510281 | ||
| Daunomycin and silicone oil for the treatment of proliferative vitreoretinopathy | Q43537051 | ||
| Long-term results of vitrectomy and perfluorocarbon gas for the treatment of severe proliferative vitreoretinopathy | Q43551067 | ||
| Giant retinal tears. Surgical techniques and results using perfluorocarbon liquids | Q43617153 | ||
| Transforming growth factor-beta 2 for the treatment of full-thickness macular holes. A prospective randomized study | Q43734011 | ||
| Evaluation of radiation therapy for experimental proliferative vitreoretinopathy in rabbits | Q44001301 | ||
| Anterior proliferative vitreoretinopathy in the silicone study. Silicone Study Report Number 10. | Q46078190 | ||
| Relaxing retinotomy with silicone oil or long-acting gas in eyes with severe proliferative vitreoretinopathy. Silicone Study Report 5. The Silicone Study Group. | Q46204414 | ||
| Classification of proliferative vitreoretinopathy used in the silicone study. The Silicone Study Group | Q46206390 | ||
| Taxol treatment of experimental proliferative vitreoretinopathy | Q46519111 | ||
| Immune response to specific molecules of the retina in proliferative vitreoretinal disorders | Q48131721 | ||
| Wendell L. Hughes Lecture. Wound healing | Q48549318 | ||
| Temporary silicone oil tamponade in the management of retinal detachment with proliferative vitreoretinopathy | Q49197569 | ||
| Circular subtotal retinectomy and inferior semicircular retinotomy: preliminary report. | Q54725016 | ||
| Immunohistologic Study of Epiretinal Membranes in Proliferative Vitreoretinopathy | Q57693445 | ||
| Cytokines in proliferative vitreoretinopathy | Q63407755 | ||
| Proliferative vitreoretinopathy. Lymphocytes in epiretinal membranes | Q67561258 | ||
| An updated classification of retinal detachment with proliferative vitreoretinopathy | Q67938098 | ||
| A prospective, randomized, clinical trial of heparin therapy for postoperative intraocular fibrin | Q67939585 | ||
| Complications associated with the use of silicone oil in 150 eyes after retina-vitreous surgery | Q67939654 | ||
| Intravitreal silicone and fluorosilicone oils: pathologic findings in rabbit eyes | Q67973269 | ||
| Vitrectomy with silicone oil or sulfur hexafluoride gas in eyes with severe proliferative vitreoretinopathy: results of a randomized clinical trial. Silicone Study Report 1 | Q68140147 | ||
| Autoimmune responsiveness to retinal IRBP, S-antigen and opsin in proliferative vitreoretinopathy | Q68412001 | ||
| Indications and results of relaxing retinotomy | Q68608249 | ||
| Extensive peripheral retinectomy combined with posterior 360 degrees retinotomy for retinal reattachment in advanced proliferative vitreoretinopathy cases | Q68608252 | ||
| Long-term inhibition of cellular proliferation by immunotoxins | Q68851500 | ||
| A biologic tissue adhesive for vitreoretinal surgery | Q69056420 | ||
| Transvitreal cyanoacrylate retinopexy in the management of complicated retinal detachment | Q69190394 | ||
| Improvement in efficacy of corticosteroid therapy in an animal model of proliferative vitreoretinopathy by pretreatment | Q69398227 | ||
| Long-term results of vitrectomy and silicone oil in 500 cases of complicated retinal detachments | Q69461867 | ||
| Fluorinated oils as experimental vitreous substitutes | Q69563787 | ||
| Transforming growth factor beta. A biologic chorioretinal glue | Q69584973 | ||
| Experimental vitreous replacement with perfluorotributylamine | Q69711056 | ||
| Low viscosity liquid fluorochemicals in vitreous surgery | Q69711060 | ||
| A fluorescein angiographic study on patients with proliferative vitreoretinopathy treated by vitrectomy and intraocular daunomycin | Q69751212 | ||
| Silicone oil in vitreoretinal surgery. Part 2: Results and complications | Q69796357 | ||
| Retinal wound healing. Cellular activity at the vitreoretinal interface | Q70011862 | ||
| Platelet-derived growth factor is chemotactic for human retinal pigment epithelial cells | Q70083229 | ||
| Isolation and identification of stimulatory and inhibitory cell growth factors in bovine vitreous | Q70284992 | ||
| Treatment of postvitrectomy fibrin formation with intraocular tissue plasminogen activator | Q70398247 | ||
| Effect of vitreous on morphologic characteristics of retinal pigment epithelial cells. A new approach to the study of proliferative vitreoretinopathy | Q70580542 | ||
| Cryotherapy during surgery for giant retinal tears and intravitreal dispersion of viable retinal pigment epithelial cells | Q70674503 | ||
| Serum contains chemoattractants for human retinal pigment epithelial cells | Q70701795 | ||
| N,N-dimethyladriamycin for treatment of experimental proliferative vitreoretinopathy: efficacy and toxicity on the rabbit retina | Q70733808 | ||
| Inhibition of experimental proliferative vitreoretinopathy in rabbits by suramin | Q70851215 | ||
| Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy | Q70962898 | ||
| 5-fluorouracil: new applications in complicated retinal detachment for an established antimetabolite | Q71307535 | ||
| Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide | Q71424975 | ||
| Postoperative retinal fibrosis--a controlled clinical study of systemic steroid therapy | Q71477310 | ||
| Treatment of retinal breaks with autologous serum in an experimental model | Q71674815 | ||
| The classification of retinal detachment with proliferative vitreoretinopathy | Q71748348 | ||
| Radiation therapy in proliferative vitreoretinopathy. A prospective randomized study | Q72067610 | ||
| Retinotomy | Q72099580 | ||
| Inflammatory cells in proliferative vitreoretinopathy subretinal membranes | Q72210826 | ||
| Vitrectomy with silicone oil or perfluoropropane gas in eyes with severe proliferative vitreoretinopathy. Silicone Study Report 3 | Q72261212 | ||
| Postoperative intraocular pressure abnormalities in the Silicone Study. Silicone Study Report 4 | Q72587645 | ||
| Silicone oil as a delivery vehicle for BCNU in rabbit proliferative vitreoretinopathy | Q72591738 | ||
| Experimental long-term vitreous replacement with purified and nonpurified perfluorodecalin | Q72602519 | ||
| Epiretinal membrane formation. Light and electron microscopic study in an experimental rabbit model | Q72624912 | ||
| Macular changes and fluorescein angiographic findings after repair of proliferative vitreoretinopathy | Q72652695 | ||
| Clinical risk factors for proliferative vitreoretinopathy after retinal detachment surgery | Q72652703 | ||
| Histopathologic study of epiretinal proliferations after vitrectomy with daunomycin and silicone oil | Q72652707 | ||
| Immunohistochemical study of cellular fibronectin in preretinal membranes | Q72652710 | ||
| Fluorouracil for the Treatment of Massive Periretinal Proliferation | Q72680562 | ||
| A comparison of 5-fluorouridine and 5-fluorouracil in an experimental model for the treatment of vitreoretinal scarring | Q72863230 | ||
| Human autologous serum for the treatment of full-thickness macular holes. A preliminary study | Q73274976 | ||
| The role of retinotomy in an experimental rabbit model of proliferative vitreoretinopathy | Q73345121 | ||
| Porcine model of proliferative vitreoretinopathy with platelets | Q73435640 | ||
| P433 | issue | 1 | |
| P921 | main subject | proliferative vitreoretinopathy | Q7249608 |
| P304 | page(s) | 3-18 | |
| P577 | publication date | 1998-07-01 | |
| P1433 | published in | Survey of Ophthalmology | Q7647088 |
| P1476 | title | Proliferative vitreoretinopathy: an overview | |
| P478 | volume | 43 |
| Q39300347 | A novel cytarabine crystalline lipid prodrug: hexadecyloxypropyl cytarabine 3',5'-cyclic monophosphate for proliferative vitreoretinopathy. |
| Q35679523 | A novel strategy to develop therapeutic approaches to prevent proliferative vitreoretinopathy |
| Q40675206 | A novel vitreous substitute of using a foldable capsular vitreous body injected with polyvinylalcohol hydrogel |
| Q37705634 | A retrospective study comparing outcomes of primary rhegmatogenous retinal detachment repair by scleral buckling and pars plana vitrectomy in Finland |
| Q36846629 | Adalimumab (tumor necrosis factor-blocker) reduces the expression of glial fibrillary acidic protein immunoreactivity increased by exogenous tumor necrosis factor alpha in an organotypic culture of porcine neuroretina |
| Q27013698 | An ocular view of the IGF-IGFBP system |
| Q80224696 | Anatomic outcome of scleral buckling surgery in primary rhegmatogenous retinal detachment |
| Q35582614 | Aqueous and alcoholic extracts of Triphala and their active compounds chebulagic acid and chebulinic acid prevented epithelial to mesenchymal transition in retinal pigment epithelial cells, by inhibiting SMAD-3 phosphorylation |
| Q36035808 | Assessment of the innate and adaptive immune system in proliferative vitreoretinopathy |
| Q44123219 | Basic fibroblast growth factor, glutamine synthetase, and interleukin-6 in vitreous fluid from eyes with retinal detachment complicated by proliferative vitreoretinopathy |
| Q36429703 | Biocompatibility of a Synthetic Biopolymer for the Treatment of Rhegmatogenous Retinal Detachment |
| Q37682216 | Biodegradable intraocular therapies for retinal disorders: progress to date |
| Q43774516 | Biodegradable microspheres for vitreoretinal drug delivery |
| Q33860093 | Biomaterials used in the posterior segment of the eye. |
| Q92797443 | Blockade of MDM2 with inactive Cas9 prevents epithelial to mesenchymal transition in retinal pigment epithelial cells |
| Q42846718 | Cell-mediated contraction of vitreous explants from chicken embryo: possibility of screening for therapeutic agents against proliferative vitreoretinal diseases |
| Q53585197 | Chemokine CXCL-1: activity in the vitreous during proliferative vitreoretinopathy. |
| Q26739751 | Classifications for Proliferative Vitreoretinopathy (PVR): An Analysis of Their Use in Publications over the Last 15 Years |
| Q55110302 | Comparison of SNP Genotypes Related to Proliferative Vitreoretinopathy (PVR) across Slovenian and European Subpopulations. |
| Q31102905 | Comprehensive analysis of inflammatory immune mediators of the intraocular fluid aspirated from the foldable capsular vitreous body filled-eyes |
| Q37651456 | Correlation between miR-148 Expression in Vitreous and Severity of Rhegmatogenous Retinal Detachment. |
| Q38963554 | Dealings between Cataract and Retinal Reattachment Surgery in PVR. |
| Q33556455 | Downregulation of lentivirus-mediated ILK RNAi on tractional force generation in human retinal Müller cells |
| Q92382402 | Effect of silicone oil on macular capillary vessel density and thickness |
| Q43861841 | Effects of ascorbic acid on retinal pigment epithelial cells |
| Q86126484 | Effects of lysyl oxidase genetic variants on the susceptibility to rhegmatogenous retinal detachment and proliferative vitreoretinopathy |
| Q42688238 | Epiretinal membrane and cystoid macular edema as predictive factors of recurrent proliferative vitreoretinopathy |
| Q38853957 | Epithelial Membrane Protein-2 in Human Proliferative Vitreoretinopathy and Epiretinal Membranes |
| Q37597415 | Epithelial membrane protein-2 (EMP2) and experimental proliferative vitreoretinopathy (PVR). |
| Q35226712 | Evaluation of supporting role of a foldable capsular vitreous body with magnetic resonance imaging in the treatment of severe retinal detachment in human eyes |
| Q37616393 | F6H8 as an Intraoperative Tool and F6H8/Silicone Oil as a Postoperative Tamponade in Inferior Retinal Detachment with Inferior PVR. |
| Q39162846 | Factor Xa and thrombin stimulate proinflammatory and profibrotic mediator production by retinal pigment epithelial cells: a role in vitreoretinal disorders? |
| Q49482040 | Final anatomic and visual outcomes appear independent of duration of silicone oil intraocular tamponade in complex retinal detachment surgery |
| Q47136272 | Fisetin inhibits epidermal growth factor-induced migration of ARPE-19 cells by suppression of AKT activation and Sp1-dependent MMP-9 expression |
| Q35546419 | Further evidence for proinflammatory nature of perfluorohexyloctane in the eye |
| Q36790553 | Glia: the fulcrum of brain diseases |
| Q34396880 | Glucosamine inhibits epidermal growth factor-induced proliferation and cell-cycle progression in retinal pigment epithelial cells |
| Q36307023 | Heavy and standard silicone oil: intraocular inflammation |
| Q47401527 | Histopathological and ophthalmoscopic evaluation of apocynin on experimental proliferative vitreoretinopathy in rabbit eyes. |
| Q44367522 | Indocyanine green-assisted peeling of the epiretinal membrane in proliferative vitreoretinopathy |
| Q36008844 | Inhibition of DNA Methylation and Methyl-CpG-Binding Protein 2 Suppresses RPE Transdifferentiation: Relevance to Proliferative Vitreoretinopathy |
| Q35027581 | Inhibition of Mdm2 sensitizes human retinal pigment epithelial cells to apoptosis |
| Q33722456 | Inhibitory Effect of Epigallocatechin Gallate (EGCG), Resveratrol, and Curcumin on Proliferation of Human Retinal Pigment Epithelial Cells In Vitro |
| Q34607101 | Inhibitory effects of resveratrol on PDGF-BB-induced retinal pigment epithelial cell migration via PDGFRβ, PI3K/Akt and MAPK pathways |
| Q98577683 | Interleukin-6 promotes proliferative vitreoretinopathy by inducing epithelial-mesenchymal transition via the JAK1/STAT3 signaling pathway |
| Q33595120 | Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy. |
| Q28361127 | Intravitreal invading cells contribute to vitreal cytokine milieu in proliferative vitreoretinopathy |
| Q37470227 | Involvement of Müller glial cells in epiretinal membrane formation |
| Q34158448 | Lutein inhibits the migration of retinal pigment epithelial cells via cytosolic and mitochondrial Akt pathways (lutein inhibits RPE cells migration). |
| Q56936128 | Macular translocation with 360 degree retinotomy for management of age-related macular degeneration with subfoveal choroidal neovascularization |
| Q54319022 | MicroRNA-29b regulates TGF-β1-mediated epithelial-mesenchymal transition of retinal pigment epithelial cells by targeting AKT2. |
| Q98613409 | MicroRNAs in the Vitreous Humor of Patients with Retinal Detachment and a Different Grading of Proliferative Vitreoretinopathy: A Pilot Study |
| Q46621860 | Myofibroblast and extracellular matrix origins in proliferative vitreoretinopathy |
| Q41620217 | Non-buckled vitrectomy for retinal detachment with inferior breaks and proliferative vitreoretinophathy. |
| Q55922446 | Nonsteroid anti-inflammatory therapy suppresses the development of proliferative vitreoretinopathy more effectively than a steroid one |
| Q35891559 | Ocular pathogenesis and immune reaction after intravitreal dispase injection in mice. |
| Q36620642 | Oxidized porous silicon particles covalently grafted with daunorubicin as a sustained intraocular drug delivery system |
| Q37445130 | Pirfenidone inhibits migration, differentiation, and proliferation of human retinal pigment epithelial cells in vitro |
| Q33932883 | Porous silicon oxide-PLGA composite microspheres for sustained ocular delivery of daunorubicin |
| Q36906404 | Potent inhibition of cicatricial contraction in proliferative vitreoretinal diseases by statins. |
| Q97884838 | Potential for endocannabinoid system modulation in ocular pain and inflammation: filling the gaps in current pharmacological options |
| Q101574255 | Predictive modeling of proliferative vitreoretinopathy using automated machine learning by ophthalmologists without coding experience |
| Q34724376 | Proliferative vitreoretinopathy-developments in adjunctive treatment and retinal pathology |
| Q28274083 | Proliferative vitreoretinopathy: current and emerging treatments |
| Q34572836 | Proliferative vitreoretinopathy: risk factors and pathobiology |
| Q90249322 | Prophylactic intravitreal 5-fluorouracil and heparin to prevent proliferative vitreoretinopathy in high-risk patients with retinal detachment: study protocol for a randomized controlled trial |
| Q43191050 | Protein tyrosine phosphatase 1B regulates migration of ARPE-19 cells through EGFR/ERK signaling pathway |
| Q48334078 | Proteome-wide Identification of Glycosylation-dependent Interactors of Galectin-1 and Galectin-3 on Mesenchymal Retinal Pigment Epithelial (RPE) Cells. |
| Q47099863 | Proteotoxic Stress Desensitizes TGF-beta Signaling Through Receptor Downregulation in Retinal Pigment Epithelial Cells |
| Q36817646 | Ranibizumab is a potential prophylaxis for proliferative vitreoretinopathy, a nonangiogenic blinding disease |
| Q38940171 | Recent perspectives on the delivery of biologics to back of the eye. |
| Q42072283 | Regulation of Na,K-ATPase β1-subunit in TGF-β2-mediated epithelial-to-mesenchymal transition in human retinal pigmented epithelial cells |
| Q37590386 | Resveratrol inhibits transforming growth factor-β2-induced epithelial-to-mesenchymal transition in human retinal pigment epithelial cells by suppressing the Smad pathway |
| Q37691345 | Retinal MMP-12, MMP-13, TIMP-1, and TIMP-2 expression in murine experimental retinal detachment. |
| Q47164525 | Retinal shortening: Ultrasonic evaluation of proliferative vitreoretinopathy |
| Q27016643 | Rhegmatogenous retinal detachment--an ophthalmologic emergency |
| Q46917842 | Risk factors for recurrent retinal detachment |
| Q60307239 | Scleral buckle surgery in Ghana: a decade comparison of the anatomic and visual outcome |
| Q43653223 | Shaken not stirred |
| Q27024666 | Signal transducer and activator of transcription 3 (STAT3) signaling in retinal pigment epithelium cells |
| Q38228354 | Silicone oil: different physical proprieties and clinical applications |
| Q58075251 | Statins in rhegmatogenous retinal detachment are associated with low intravitreal angiopoietin-2, VEGF and MMP-2 levels, and improved visual acuity gain in vitrectomized patients |
| Q45991471 | Subretinal fluid from rhegmatogenous retinal detachment and blood induces the expression of ICAM-1 in the human retinal pigment epithelium (ARPE-19) in vitro. |
| Q40533401 | The PI3K/Akt pathway mediates the expression of type I collagen induced by TGF-β2 in human retinal pigment epithelial cells |
| Q35070151 | The T309G MDM2 gene polymorphism is a novel risk factor for proliferative vitreoretinopathy |
| Q48297024 | The influence of systemic renin-angiotensin-inhibition on ocular cytokines related to proliferative vitreoretinopathy |
| Q35221178 | The role of Bcl-xL in mouse RPE cell survival |
| Q33786878 | The tight junction associated signalling proteins ZO-1 and ZONAB regulate retinal pigment epithelium homeostasis in mice |
| Q36531100 | Three-Year Efficacy and Safety of a Silicone Oil-Filled Foldable-Capsular-Vitreous-Body in Three Cases of Severe Retinal Detachment |
| Q103804621 | Topical delivery of a small molecule RUNX1 transcription factor inhibitor for the treatment of proliferative vitreoretinopathy |
| Q39953591 | Transcriptional regulatory network analysis during epithelial-mesenchymal transformation of retinal pigment epithelium |
| Q21134936 | Transcriptomic analysis of human retinal detachment reveals both inflammatory response and photoreceptor death |
| Q39520301 | Trichostatin A Inhibits Retinal Pigmented Epithelium Activation in an In Vitro Model of Proliferative Vitreoretinopathy. |
| Q44113262 | Triple cycle audit of primary retinal detachment surgery |
| Q46702110 | Upregulation of TGF-ß1 in experimental proliferative vitreoretinopathy is accompanied by epithelial to mesenchymal transition |
| Q90952571 | Utility of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for an In Vitro Model of Proliferative Vitreoretinopathy |
| Q35943908 | Vascular endothelial growth factor A competitively inhibits platelet-derived growth factor (PDGF)-dependent activation of PDGF receptor and subsequent signaling events and cellular responses |
| Q36666791 | Vitreous fluid biomarkers. |
| Q36822065 | Vitreous induces heme oxygenase-1 expression mediated by transforming growth factor-beta and reactive oxygen species generation in human retinal pigment epithelial cells |
| Q92351063 | Vitreous levels of Lipocalin-2 on patients with primary rhegmatogenous retinal detachment |
| Q34422007 | Vitreous substitutes: the present and the future |
Search more.